LUNAC
LIVE

Serial Number

79289877

Owner

Lunac Therapeutics Limited

Attorney

Matthew L. Frisbee

Filing Date

Jan 27, 2020

Add to watchlist:

No watchlists yet
View on USPTO

LUNAC Trademark

Serial Number: 79289877 • Registration: 6405774

LUNAC is a trademark filed by Lunac Therapeutics Limited on January 27, 2020. The trademark is classified under Class 5 (Pharmaceuticals), Class 40 (Treatment & Processing), Class 42 (Computer & Scientific). The application is currently registered and active.

Owner Contact Info

Lunac Therapeutics Limited (2 trademarks)

Secretariat,

Entity Type: 99

Trademark Details

Filing Date

January 27, 2020

Registration Date

July 6, 2021

Published for Opposition

April 20, 2021

Goods & Services

custom manufacture of chemicals, medicines, pharmaceuticals and anticoagulants; custom manufacture of therapeutic products and medical diagnostic products in the nature of pharmaceuticals for the treatment of blood disorders, blood clots and to prevent blood coagulation; consultancy, advisory and information in connection with all of the aforementioned services, namely, providing advisory services regarding the custom manufacture of pharmaceuticals for others

Medical and veterinary preparations, namely pharmaceutical preparations for the treatment of blood disorders, blood clots and to prevent blood coagulation; pharmaceuticals, namely pharmaceutical preparations for the treatment of blood disorders, blood clots and to prevent blood coagulation; medicines, namely pharmaceutical preparations for the treatment of blood disorders; therapeutic medicines and pharmaceuticals, namely pharmaceutical preparations for the treatment of blood disorders; medical diagnostic products, namely diagnostic preparations for medical purposes; anticoagulants; anticoagulants for the treatment of medical conditions; anticoagulants for the treatment of thrombosis and blood clots; anticoagulants for use in the discovery, preclinical and clinical development of therapeutic products and medical diagnostic products; medicines and pharmaceuticals for use in the discovery, preclinical and clinical development of therapeutic products and medical diagnostic products, namely anticoagulants

Scientific and technological services, namely, providing scientific research for medical purposes in the field of blood disorders, blood clots and to prevent blood coagulation; research and design in relation to science, technology, pharmaceuticals, medicine, blood, thrombosis and anticoagulants, namely, providing scientific research for medical purposes in the field of blood disorders, blood clots and to prevent blood coagulation; preparation of scientific reports on anticoagulants for medical and veterinary purposes; engineering of medicines and pharmaceuticals; bimolecular engineering of anticoagulants, namely, the manipulation of oral small molecules for use as anticoagulants; engineering of anticoagulants; engineering of medicines and pharmaceuticals for the treatment of thrombosis and blood clotting; scientific services relating to the discovery, preclinical and clinical development of therapeutic and medical diagnostic products, namely, providing scientific research for medical purposes in the field of blood disorders, blood clots and to prevent blood coagulation; consultancy, advisory and information in connection with all of the aforementioned services, namely, advising regarding scientific research for medical purposes in the field of blood disorders, blood clots and to prevent blood coagulation

Filing History

TEAS CHANGE OF CORRESPONDENCE RECEIVED
Jun 17, 2025 TCCA
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Jun 17, 2025 ARAA
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Jun 17, 2025 REAP
FINAL DECISION TRANSACTION PROCESSED BY IB
Nov 29, 2021 FINO
FINAL DISPOSITION NOTICE SENT TO IB
Nov 9, 2021 FICS
FINAL DISPOSITION PROCESSED
Nov 9, 2021 FIMP
FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
Oct 6, 2021 FICR
REGISTERED-PRINCIPAL REGISTER
Jul 6, 2021 R.PR
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Apr 20, 2021 NPUB
PUBLISHED FOR OPPOSITION
Apr 20, 2021 PUBO
NOTIFICATION PROCESSED BY IB
Apr 18, 2021 GPNX
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
Mar 31, 2021 OPNS
NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB
Mar 31, 2021 OP2R
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Mar 31, 2021 NONP
APPROVED FOR PUB - PRINCIPAL REGISTER
Mar 12, 2021 CNSA
EXAMINER'S AMENDMENT ENTERED
Mar 11, 2021 XAEC
NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
Mar 11, 2021 GNEN
EXAMINERS AMENDMENT E-MAILED
Mar 11, 2021 GNEA
EXAMINERS AMENDMENT -WRITTEN
Mar 11, 2021 CNEA
TEAS/EMAIL CORRESPONDENCE ENTERED
Feb 25, 2021 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Feb 24, 2021 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Feb 24, 2021 TROA
REFUSAL PROCESSED BY IB
Sep 27, 2020 RFNT
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
Sep 6, 2020 RFCS
REFUSAL PROCESSED BY MPU
Sep 2, 2020 RFRR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
Jul 28, 2020 RFCR
APPLICATION FILING RECEIPT MAILED
Jul 28, 2020 MAFR
NON-FINAL ACTION WRITTEN
Jul 27, 2020 CNRT
ASSIGNED TO EXAMINER
Jul 24, 2020 DOCK
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Jul 24, 2020 NWOS
SN ASSIGNED FOR SECT 66A APPL FROM IB
Jul 23, 2020 REPR